Division of Physical Medicine and Rehabilitation, Department of Orthopedic Surgery, University of Utah, Salt Lake City, Utah, USA
Division of Physical Medicine and Rehabilitation, Department of Orthopedic Surgery, University of Utah, Salt Lake City, Utah, USA.
Reg Anesth Pain Med. 2021 Sep;46(9):813-819. doi: 10.1136/rapm-2021-102514. Epub 2021 May 14.
The objective of this study was to evaluate the long-term effectiveness of catheter-directed cervical interlaminar epidural steroid injection with triamcinolone compared with cervical transforaminal steroid injection with dexamethasone for the treatment of refractory unilateral radicular pain.
Prospective, randomized, comparative trial.
The primary outcome was the proportion of participants with ≥50% Numeric Rating Scale 'dominant pain' (the greater of arm vs neck) reduction from baseline. Secondary outcomes included ≥30% Neck Disability Index reduction and Patient Global Impression of Change response indicating 'much improved' or 'very much improved'.
Data from 117 participants (55.6% women; 52.3±12.5 years of age; body mass index, 28.2±6.5 kg/m) were analyzed. The proportion of participants who experienced ≥50% pain reduction at 1 month, 3 months, and 6 months has been previously reported. At 1 year, 61.2% (95% CI, 46.9% to 73.9%) of the catheter group compared with 51.9% (95% CI, 38.4% to 65.2%) of the transforaminal group reported ≥50% 'dominant' pain reduction (p=0.35). The proportion of participants who experienced ≥30% improvement in Neck Disability Index score was 60.4% (95% CI, 45.9% to 73.3%) and 47.1% (95% CI, 33.7% to 60.8%) in the catheter and transforaminal groups (p=0.18). Patient Global Impression of Change improvement was similar in both groups: 60.5% (95% CI, 44.2% to 74.8%) and 57.5% (95% CI, 41.7% to 71.9%) of the catheter and transforaminal groups reported being 'much improved' or 'very much improved', respectively (p=0.79).
Both cervical catheter-directed interlaminar epidural injection and cervical transforaminal steroid injection were effective in reducing pain and disability in the majority of participants with refractory unilateral cervical radiculopathy for up to 1 year.
本研究旨在评估曲安奈德颈椎间硬膜外腔导管定向注射与地塞米松颈椎椎间孔注射治疗难治性单侧神经根痛的长期疗效。
前瞻性、随机、对照试验。
主要结局为从基线开始,≥50%数字评定量表“优势疼痛”(手臂与颈部中较大者)减轻的参与者比例。次要结局包括≥30%颈痛残疾指数减轻和患者整体变化印象反应表示“明显改善”或“非常明显改善”。
对 117 名参与者(55.6%女性;52.3±12.5 岁;体重指数,28.2±6.5kg/m)的数据进行了分析。先前已报告过 1 个月、3 个月和 6 个月时≥50%疼痛减轻的参与者比例。在 1 年时,导管组有 61.2%(95%可信区间,46.9%至 73.9%),而椎间孔组有 51.9%(95%可信区间,38.4%至 65.2%)的参与者报告≥50%“优势”疼痛减轻(p=0.35)。颈痛残疾指数评分≥30%改善的参与者比例为导管组 60.4%(95%可信区间,45.9%至 73.3%),椎间孔组为 47.1%(95%可信区间,33.7%至 60.8%)(p=0.18)。两组患者的整体变化印象改善相似:导管组和椎间孔组分别有 60.5%(95%可信区间,44.2%至 74.8%)和 57.5%(95%可信区间,41.7%至 71.9%)的患者报告为“明显改善”或“非常明显改善”(p=0.79)。
对于难治性单侧颈椎神经根病患者,颈椎间硬膜外腔导管定向注射和颈椎椎间孔注射均能有效减轻疼痛和残疾,在 1 年内大多数患者都能达到这一效果。